Figure 2.
PAC/SIR/TAC inhibits inflammatory Th1 and Th17 cells, while increasing Th2 cells. (A) %CD4+ Th1 cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (B-C) Percentage (B) and absolute number (C) of CD4+ Th1 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs recommended phase 2 dose (RP2D) PAC/SIR/TAC. (D) %CD4+ Th17 cells pretransplant and at days +21 and +100 on phase 2 PAC/SIR/TAC. (E-F) Percentage (E) and absolute number (F) of CD4+ Th17 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. (G) %CD4+ Th2 cells pretransplant and at days +21 and +100 on phase 2 PAC/SIR/TAC. (H-I) Percentage (H) and absolute number (I) of CD4+ Th2 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. ∗P < .05, ∗∗P = .01-.001, ∗∗∗∗P < .0001.

PAC/SIR/TAC inhibits inflammatory Th1 and Th17 cells, while increasing Th2 cells. (A) %CD4+ Th1 cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (B-C) Percentage (B) and absolute number (C) of CD4+ Th1 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs recommended phase 2 dose (RP2D) PAC/SIR/TAC. (D) %CD4+ Th17 cells pretransplant and at days +21 and +100 on phase 2 PAC/SIR/TAC. (E-F) Percentage (E) and absolute number (F) of CD4+ Th17 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. (G) %CD4+ Th2 cells pretransplant and at days +21 and +100 on phase 2 PAC/SIR/TAC. (H-I) Percentage (H) and absolute number (I) of CD4+ Th2 cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. ∗P < .05, ∗∗P = .01-.001, ∗∗∗∗P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal